Top Suppliers:I want be here
Related CAS#:
164083-84-5 886047-22-9
152755-31-2 172895-15-7
186544-27-4 1779796-27-8
193281-05-9 107889-32-7
137328-52-0 176199-48-7
7756-82-3 947331-11-5
5825-72-9 2229453-09-0
2229594-12-9 2228748-60-3
2748242-64-8 2228503-63-5
2229543-59-1 2820446-88-4

164083-84-5

164083-84-5 structure
164083-84-5 structure
  • Name: LY 311727
  • Chemical Name: 3-[3-(2-amino-2-oxoethyl)-1-benzyl-2-ethylindol-5-yl]oxypropylphosphonic acid
  • CAS Number: 164083-84-5
  • Molecular Formula: C22H27N2O5P
  • Molecular Weight: 430.43400
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Phospholipase
  • Create Date: 2017-06-10 14:55:27
  • Modify Date: 2025-08-25 17:29:43
  • LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 <1 μM for group IIA sPLA2). sPLA2 is an important proinflammatory enzyme[1][2].
Name 3-[3-(2-amino-2-oxoethyl)-1-benzyl-2-ethylindol-5-yl]oxypropylphosphonic acid
Synonyms (3-{[3-(2-Amino-2-Oxoethyl)-1-Benzyl-2-Ethyl-1h-Indol-5-Yl]oxy}propyl)phosphonic Acid
Description LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 <1 μM for group IIA sPLA2). sPLA2 is an important proinflammatory enzyme[1][2].
Related Catalog
Target

sPLA2[1]

In Vitro LY-311727 (0.1-10 μM) suppresses the contractile responses induced by human non-pancreatic secretory phospholipase A2 (hnps-PLA2), in a concentration related manner[1]. LY-311727 nearly abolishes the hnps-PLA2 responses at 1μM, while it failed to suppress porcine pancreatic PLA2 concentration response curves at the same concentration[1]. LY-311727 displays 1,500-fold selectivity when assayed against porcine pancreatic s-PLA2[1].
In Vivo LY-311727 (3-30 mg/kg; i.v.) dramatically suppresses the circulating enzyme activity in mice with Mt-sPLA2 transgenic the intravenous (i.v.) administration[2]. Animal Model: C57BL/6J mice, metallothionein promoter-human secretory PLA2 minigene (Mt-sPLA2) transgenic mice model[2] Dosage: 3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Intravenous injection Result: Significantly and dose dependently suppressed the PLA2 activity in the serum.
References

[1]. R W Schevitz, et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995 Jun;2(6):458-65.

[2]. N Fox, et al. Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors. Eur J Pharmacol. 1996 Jul 18;308(2):195-203.

[3]. M Murakami, et al. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem. 1998 Jun 5;273(23):14411-23.
Density 1.32g/cm3
Boiling Point 758.2ºC at 760mmHg
Molecular Formula C22H27N2O5P
Molecular Weight 430.43400
Flash Point 412.3ºC
Exact Mass 430.16600
PSA 125.58000
LogP 4.37610
Vapour Pressure 3.69E-24mmHg at 25°C
Index of Refraction 1.619
Storage condition 2-8°C
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:164083-84-5 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 164083-84-5 | Chemsrc address: https://m.chemsrc.com/en/baike/4268.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved